After establishing a relationship with Harvard Medical School, TELL was selected to perform studies on speech changes in patients with intracranial electrodes suffering from epilepsy and Parkinson’s disease.

Adolfo García, CSO and co-founder of TELL, comments that «we have a long-standing connection with Harvard, and a month ago we signed an agreement to evaluate how the implantation of these electrodes could impact speech».

You can read the full article here.